GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Awakn Life Sciences Corp (OTCPK:AWKNF) » Definitions » Net-Net Working Capital

Awakn Life Sciences (Awakn Life Sciences) Net-Net Working Capital : $-0.03 (As of Jan. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Awakn Life Sciences Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Awakn Life Sciences's Net-Net Working Capital for the quarter that ended in Jan. 2024 was $-0.03.

The industry rank for Awakn Life Sciences's Net-Net Working Capital or its related term are showing as below:

AWKNF's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 4.15
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Awakn Life Sciences Net-Net Working Capital Historical Data

The historical data trend for Awakn Life Sciences's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Awakn Life Sciences Net-Net Working Capital Chart

Awakn Life Sciences Annual Data
Trend Jan21 Jan22 Jan23 Jan24
Net-Net Working Capital
- -0.06 -0.07 -0.03

Awakn Life Sciences Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.10 -0.03 -0.03 -0.03

Competitive Comparison of Awakn Life Sciences's Net-Net Working Capital

For the Biotechnology subindustry, Awakn Life Sciences's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Awakn Life Sciences's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Awakn Life Sciences's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Awakn Life Sciences's Price-to-Net-Net-Working-Capital falls into.



Awakn Life Sciences Net-Net Working Capital Calculation

Awakn Life Sciences's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Jan. 2024 is calculated as

Net-Net Working Capital(A: Jan. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.303+0.75 * 0.005+0.5 * 0-1.545
-0-0)/39.0912
=-0.03

Awakn Life Sciences's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jan. 2024 is calculated as

Net-Net Working Capital(Q: Jan. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.303+0.75 * 0.005+0.5 * 0-1.545
-0-0)/39.0912
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Awakn Life Sciences  (OTCPK:AWKNF) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Awakn Life Sciences Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Awakn Life Sciences's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Awakn Life Sciences (Awakn Life Sciences) Business Description

Traded in Other Exchanges
Address
301?217 Queen Street West, Toronto, ON, CAN, M5V 0R2
Awakn Life Sciences Corp is a clinical-stage biotechnology company intended to develop therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder. The Company focuses on Alcohol Use Disorder (AUD), a condition affecting the people in the US and key international markets and many people globally for which the current standard of care is inadequate, enabling to provide breakthrough therapeutics to addiction sufferers in desperate need.

Awakn Life Sciences (Awakn Life Sciences) Headlines